These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Emerging Role of CD8 Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F Front Immunol; 2018; 9():1904. PubMed ID: 30158938 [TBL] [Abstract][Full Text] [Related]
5. Tumor-resident memory T cells as a biomarker of the response to cancer immunotherapy. Damei I; Trickovic T; Mami-Chouaib F; Corgnac S Front Immunol; 2023; 14():1205984. PubMed ID: 37545498 [TBL] [Abstract][Full Text] [Related]
6. Implication of CD69 Kim HD; Jeong S; Park S; Lee YJ; Ju YS; Kim D; Song GW; Lee JH; Kim SY; Shin J; Shin EC; Hwang S; Yoo C; Park SH Liver Int; 2021 Apr; 41(4):764-776. PubMed ID: 33548061 [TBL] [Abstract][Full Text] [Related]
7. Spatial features of specific CD103 Yang G; Cai S; Hu M; Li C; Yang L; Zhang W; Sun J; Sun F; Xing L; Sun X J Transl Med; 2024 Jan; 22(1):27. PubMed ID: 38183111 [TBL] [Abstract][Full Text] [Related]
8. Functional Heterogeneity of CD4 Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P Front Immunol; 2018; 9():2654. PubMed ID: 30505306 [TBL] [Abstract][Full Text] [Related]
9. Activated tissue resident memory T-cells (CD8+CD103+CD39+) uniquely predict survival in left sided "immune-hot" colorectal cancers. Talhouni S; Fadhil W; Mongan NP; Field L; Hunter K; Makhsous S; Maciel-Guerra A; Kaur N; Nestarenkaite A; Laurinavicius A; Willcox BE; Dottorini T; Spendlove I; Jackson AM; Ilyas M; Ramage JM Front Immunol; 2023; 14():1057292. PubMed ID: 37251410 [TBL] [Abstract][Full Text] [Related]
10. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272 [TBL] [Abstract][Full Text] [Related]
12. Cancer-specific tissue-resident memory T-cells express ZNF683 in colorectal cancer. Kitakaze M; Uemura M; Hara T; Chijimatsu R; Motooka D; Hirai T; Konno M; Okuzaki D; Sekido Y; Hata T; Ogino T; Takahashi H; Miyoshi N; Ofusa K; Mizushima T; Eguchi H; Doki Y; Ishii H Br J Cancer; 2023 May; 128(10):1828-1837. PubMed ID: 36869093 [TBL] [Abstract][Full Text] [Related]
13. Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. Yu Y; Zeng H; Jin K; You R; Liu Z; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z Cancer Immunol Immunother; 2022 Sep; 71(9):2117-2126. PubMed ID: 35041031 [TBL] [Abstract][Full Text] [Related]
14. Tumor-Infiltrating CD103+ Tissue-Resident Memory T Cells and CD103-CD8+ T Cells in HNSCC Are Linked to Outcome in Primary but not Metastatic Disease. von Witzleben A; Ellis M; Thomas GJ; Hoffmann TK; Jackson R; Laban S; Ottensmeier CH Clin Cancer Res; 2024 Jan; 30(1):224-234. PubMed ID: 37874322 [TBL] [Abstract][Full Text] [Related]
15. Resident memory T cells, critical components in tumor immunology. Mami-Chouaib F; Blanc C; Corgnac S; Hans S; Malenica I; Granier C; Tihy I; Tartour E J Immunother Cancer; 2018 Sep; 6(1):87. PubMed ID: 30180905 [TBL] [Abstract][Full Text] [Related]
16. Significance of CD103 Natsuki S; Tanaka H; Nishiyama M; Deguchi S; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Maeda K BMC Cancer; 2023 Oct; 23(1):1011. PubMed ID: 37864146 [TBL] [Abstract][Full Text] [Related]
17. TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. Liu Z; Zeng H; Jin K; Yu Y; You R; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z Br J Cancer; 2022 May; 126(9):1310-1317. PubMed ID: 35039625 [TBL] [Abstract][Full Text] [Related]
18. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436 [TBL] [Abstract][Full Text] [Related]
19. Cancer stem-like cells evade CD8 Corgnac S; Damei I; Gros G; Caidi A; Terry S; Chouaib S; Deloger M; Mami-Chouaib F J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35418483 [TBL] [Abstract][Full Text] [Related]
20. Distribution, phenotype, functional and clinical relevance of CD8 Shen Y; Li XL; Li YX; Shan ZG; Zhao YL; Cheng P; Zhao Z; Zhang JY; Chen W; Zhuang Y; Ma DY; Zou QM; Qiu Y; Peng LS Cancer Immunol Immunother; 2022 Jul; 71(7):1645-1654. PubMed ID: 34767045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]